Supplementary Data 1

Complete Eligibility Criteria

Inclusion Criteria

Patients were eligible for inclusion in COAST-Y only if they met the following criteria:

1. Have completed the final study visit in COAST-V (NCT02696785), COAST-W (NCT02696798) or COAST-X (NCT02757352). (Note: patients from COAST-X were not eligible if they permanently discontinued ixekizumab and were receiving a tumour necrosis factor (TNF) inhibitor.)

2. Must have agreed to use a reliable method of birth control

   - If a male patient, patient agrees to use a reliable method of birth control during the study and for at least 12 weeks following the last dose of investigational product, whichever is longer.

   - If a female patient, patient was a woman of childbearing potential who tested negative for pregnancy and agreed to use a reliable method of birth control or remain abstinent during the study and for at least 12 weeks following the last dose of investigational product, whichever is longer. Methods of birth control included, but were not limited to, condoms with spermicide, male sterilisation, oral contraceptives, contraceptive patch, injectable or implantable contraceptives, intrauterine device, vaginal ring, or diaphragm with contraceptive gel.

   (Note: Where required by regulation, a highly effective method of birth control was required. A highly effective method of birth control was defined as one that results in a low failure rate [that is, <1% per year] when used consistently and correctly, such as male sterilisation, oral contraceptives, contraceptive patch, injectable or implantable contraceptives, intrauterine device, or vaginal ring).

OR
• If a female patient was a woman of nonchildbearing potential, she was not required to use any methods of birth control. Nonchildbearing potential was defined as:

- Women who have had surgical sterilisation (hysterectomy, bilateral oophorectomy, or tubal ligation).
- or -
- Women who were ≥60 years of age.
- or -
- Women ≥40 and <60 years of age who have had a cessation of menses for ≥12 months and a follicle stimulating hormone (FSH) test confirming nonchildbearing potential (≥40 mIU/mL or ≥40 IU/L).

[3.] Have given written informed consent approved by Eli Lilly or its designee, and the Investigational Review Board (IRB)/Ethical Review Board (ERB) governing the site.

**Exclusion Criteria**

Patients were excluded from study enrolment if they met any of the following criteria:

[4.] Had significant uncontrolled cerebro cardiovascular events (for example, myocardial infarction, unstable angina, unstable arterial hypertension, severe heart failure, or cerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine, haematologic, neuropsychiatric disorders, or abnormal laboratory values that developed during a previous ixekizumab study that, in the opinion of the investigator, posed an unacceptable risk to the patient if investigational product continued to be administered.

[5.] Had a known hypersensitivity to ixekizumab or any component of this investigational product.
[6.] Had investigational product permanently discontinued during a previous ixekizumab study

[7.] Had temporary investigational product interruption at any time during or at the final study visit of a previous ixekizumab study and, in the opinion of the investigator, restarting ixekizumab posed an unacceptable risk for the patient's participation in the study.

[8.] Had any other condition that, in the opinion of the investigator, rendered the patient unable to understand the nature, scope, and possible consequences of the study or precluded the patient from following and completing the protocol.

[9.] Were enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.